Angel-funded Siamab completes £166m exit with large commercial-stage biopharma

Image: Siamab will develop and commercialise antibody-based products targeting a tumor-associated carbohydrate antigen identified by its proprietary TACA discovery platform. Photo: courtesy of Arek Socha from Pixabay.